Skye Bioscience, Inc.
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Filed Herewith
*Exhibits and/or schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish supplementally copies of any of the omitted exhibits and schedules upon request by the SEC; provided, however, that the registrant may request confidential treatment pursuant to Rule 24b-2 under the Exchange Act for any exhibits or schedules so furnished.
† Portions of this exhibit have been omitted in compliance with Regulation S-K Item 601(b)(10)(iv).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Skye Bioscience, Inc.,a Nevada corporation | ||
| August 14, 2026 | By: | /s/ Punit Dhillon |
|---|---|---|
| Punit Dhillon | ||
| Its: | Chief Executive Officer, President, Secretary and Director(Principal Executive Officer) | |
| August 14, 2026 | By: | /s/ John P. Sharp |
| John P. Sharp | ||
| Its: | Chief Financial Officer(Principal Financial and Accounting Officer) | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.